reduced the bacterial burden in Mycobacterium tuberculosis (Mtb)-infected macrophages by 2-23 logs over six days. Despite poor stability in solution and a short half-life in rodents, treatment of 24 chronically infected mice revealed significant reductions of bacterial burden in the lungs and 25 spleens. Our results show that meropenem has activity in two in vivo systems but stability and 26 pharmacokinetics of long-term administration will offer significant challenges to clinical 27 evaluation. 28
29
The burden of tuberculosis (TB) continues to rise with significant increases in drug 30 resistance in the developing world (19). Rising rates of multidrug resistant (MDR) and extensive 31 drug resistant (XDR)-TB continues primarily due to inadequate treatment programs, poor 32 laboratory capacity and the lack of public health infrastructures needed to manage the disease 33 (19). Demonstration of activity against M. tuberculosis (Mtb) in vitro does not guarantee in vivo 34 potency because of differences in the microenvironment within which bacteria reside (16). 35
Carbapenems are the most potent β-lactams and were developed in the 1980's to 45 enhance resistance to β-lactamases (4, 11). Meropenem is a broad-spectrum carbapenem 46 active against several clinically relevant Gram-positive and Gram-negative aerobes and 47 similarly short half-lives ranging from 3-10 hrs. 70
Because of this short half-life we examined intracellular killing by administering 71 carbapenems to infected macrophages 3 times a day (every 8 hrs) with media changes every 72 two days. No evidence of cell toxicity was found under these conditions even at concentrations 73 as high as 400μg/mL of these carbapenems in combination with clavulanic acid up to 200μM 74 (data not shown). Murine J774A.1 macrophages were then infected with H37Rv at a multiplicity 75 of 1-2 bacilli per cell and subsequently treated with various carbapenems at concentrations 76 equivalent to the known C max values in humans receiving standard therapeutic doses (50μg/mL 77 for meropenem, imipenem and ertapenem, 30μg/mL for doripenem and 10 μg/mL for 78 faropenem). Two control drugs rifampicin and isoniazid were also dosed once a day at the 79 human equivalent C max (5μg/mL) and also had their media replaced on days 2 and 4. Treated 80 macrophages were lysed at the indicated times and serial dilutions were plated for enumeration 81 of CFU (Figure 1 ). These data showed significant growth arrest of intracellular H37Rv by two 82 days (p=0.05) and highly significant killing with all carbapenems by four and six days (p=0.01 and 83 0.001 for meropenem, for example, at 4 and 6 days, respectively). At six days, the carbapenems 84 demonstrated a 1.5 -2.0 log reduction in bacterial numbers compared to untreated controls 85 with imipenem and meropenem having the largest effect. For comparison, isoniazid and 86 rifampicin controls demonstrated a 2-log kill over the same time period. 87
To examine efficacy in an animal model, we infected 30 C57Bl/6 mice with M. 88 tuberculosis H37Rv and allowed the infection to progress to a chronic stage. Three months after 89 infection the mice were divided into three groups of 10 and therapy was initiated. One group 90 was treated with meropenem alone at 300mg/kg by subcutaneous injection twice daily, a 91 second group received meropenem at the same dose but in addition was given twice daily 92 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from 50mg/kg oral doses of clavulanic acid, the final group received vehicle control treatment (PBS). 93
Five mice from each treatment group were sacrificed 2 weeks later with the remaining five 94 sacrificed at 4 weeks of treatment and bacterial burden in both lung and spleen were 95 enumerated. The data in Figure 2 illustrates that meropenem did in fact show activity in this 96 very stringent chronic mouse model. Compared to the control group both meropenem alone or 97 in combination with clavulanic acid significantly reduced CFU in both lung and spleen after two 98 weeks of treatment (p=0.008 and p=0.002 ANOVA, respectively) with a further modest 99 reduction in bacterial burden observed after four weeks of therapy. Clavulanic acid did not 100
show a statistically significant enhancement of killing in the lungs or spleen at either time point. 101
We also planned to conduct an efficacy study in TB-infected NZW rabbits, which develop 102 hypoxic pulmonary lesions (16), therefore we determined pharmacokinetic parameters and 103 tolerability in uninfected rabbits for meropenem-clavulanate at doses of 75mg/kg and 125 104 mg/kg, respectively. Drugs were delivered sequentially by I.V. bolus in four rabbits. Blood was 105 drawn at scheduled time points and plasma obtained for determination of serum 106 concentrations. Data obtained from the four animals was pooled and evaluated using Graphpad 107 PRISM 5.0 with single decay curve and AUC analyses. PK plots are a representation of pooled 108 data from all four animals (Figure 2) . The mean C 0 , t 1/2 and AUC were 2.5 mg/mL, 12.1 min, and 109 15.2 mg-min/mL, respectively, for meropenem-clavulanic acid co-administration. Because of this 110 relatively low exposure we also repeated this PK study with the addition of cilastatin, to prevent 111 hydrolysis of meropenem by DHP-1 (renal dihydropeptidase 1). Treatment of rabbits with 112 cilastatin (75 mg/kg) increased exposure and the corresponding PK parameters were 3.2 mg/mL, 113 22.0 min, and 51.5 mg-min/mL, respectively. Cilastatin therefore increased the exposure by 4 114 times even though the half-life was not significantly increased. Unfortunately, the increased 115 compared to other species and that rabbits had a relatively high degree of enzymatic activity (6). 121 Therefore, we hoped that co-administration of cilastatin would substantially reduce renal 122 hydrolysis and help maintain the levels of active compound in circulation. It is noted that 123 meropenem is considered more stable to DHP-1 hydrolysis than imipenem due to its 1-β methyl 124 side chain and the steric hindrance associated with the secondary amine of the C-2 side chain. 
